Procter & Gamble Health Reports Strong FY26 Performance with ₹326.91 Crore Profit and ₹205 Dividend

Procter & Gamble Health Ltd. announced its financial results for the fiscal year ended March 31, 2026, reporting a profit after tax (PAT) of ₹326.91 crore on revenues of ₹1407.97 crore. The company has also declared a substantial total dividend of ₹205 per equity share for the fiscal year.

Reader Takeaway: Strong profit growth driven by focused strategy and high dividend payout, but regulatory risks loom.

What just happened

For the full fiscal year 2025-26, Procter & Gamble Health achieved revenues of ₹1407.97 crore and a profit after tax of ₹326.91 crore. This compares to a nine-month period in the previous fiscal year (2024-25) which saw revenues of ₹934.17 crore and PAT of ₹234.41 crore. The company's operating profit margin stood at 31.56% for FY26, a slight decrease from 32.99% in FY25.

Why this matters

The strong financial performance demonstrates the company's effective execution of its integrated growth strategy, particularly its focus on the core Vitamins, Minerals, and Supplements (VMS) portfolio. The significant total dividend payout of ₹205 per share, including an interim dividend of ₹160 (with a special ₹50 component) and a recommended final dividend of ₹45, signals a commitment to shareholder returns.

The backstory

Procter & Gamble Health has been strategically expanding its product offerings and market reach. Recent developments include the launch of Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. A notable strategic shift was the transition of 'Evion 400' from a prescription-only product to an Over-the-Counter (OTC) offering, aiming to capture a wider consumer base. The company also entered the fatty liver health segment with 'Evion L5000'.

What changes now

With the successful FY26 results and a high dividend payout, the company is poised for continued growth. The strategic initiatives, including new product launches and OTC transitions, are expected to drive future revenue streams. Investors will be looking for sustained performance and market acceptance of these new strategies.

Risks to watch

The company faces regulatory risks inherent in the pharmaceutical and health supplement sectors, including potential impacts from pricing regulations and food and drug administration requirements. Supply chain dependencies, particularly on contract manufacturing and raw material costs, are also watch points that could affect operational consistency and profitability.

Peer comparison

While specific peer financial data for the same period isn't provided in the filing, the company's focus on the VMS and health supplement market places it alongside other nutraceutical and pharmaceutical players in India. Its operating profit margin of over 30% indicates strong operational efficiency, though direct comparison requires a like-for-like period and scope.

Context metrics (time-bound)

• FY2025-26 Revenue: ₹1407.97 crore (12 months)
• FY2025-26 PAT: ₹326.91 crore (12 months)
• FY2024-25 Revenue: ₹934.17 crore (9 months)
• FY2024-25 PAT: ₹234.41 crore (9 months)
• Total Dividend declared for FY2025-26: ₹205 per share

Note: Direct comparison of financial metrics between FY2025-26 and FY2024-25 is impacted by the difference in reporting periods (12 months vs. 9 months).

What to track next

Investors should monitor the company's progress in integrating its new product launches, the success of the 'Evion 400' OTC transition, and its ability to manage regulatory challenges and supply chain dynamics. Continued focus on the core VMS portfolio and market expansion will be key indicators.